Boston-based provider Mass General Brigham is teaming up with DTx company Better Therapeutics on a real-world data study collaboration focused on diabetes. Specifically, the organizations will be looking at the effectiveness and utilization of Better Therapeutic's prescription digital therapeutic on delivering virtual therapies to patients with Type 2 diabetes.
Patients enrolled in the study...
Researchers at the Auckland Bioengineering Institute in the University of Auckland have created a portable technology that senses temperature changes to detect feet complications among persons with type 2 diabetes.
The research team, led by Suranga Nanayakkara, an associate professor at the university, recently received funding under the Research Activation Grant of the government's Health...
A new study jointly conducted by digital chronic care management tool Omada and Evidation Health found that patients using Omada’s diabetes management program reduced their A1c level and average of 0.8 over the course of the clinical research.
The study included a total of 195 participants with Type 2 diabetes who had an average baseline A1c of 8.93%. Researchers reported that those participants...
UnitedHealth Group announced plans this morning to distribute a device-driven diabetes management model to 230,000 employer-sponsored members with Type 2 diabetes at no additional cost.
The pilot program, called Level2 by UnitedHealthcare, provides members with a Dexcom G6 continuous glucose monitor (CGM) that connects to their smartphone, a Fitbit activity tracker, personalized coaching and...
WellDoc's BlueStar chronic disease-management tool has picked up another 510(k) FDA clearance that will allow it to support adult Type 2 diabetes patients using long-acting basal insulin. The feature was announced by WellDoc this morning, but cleared by the agency in April, according to a listing on its website.
The new capability takes the form of a new program within the prescription BlueStar...
Type 2 diabetes patients who received a continuous glucose monitoring (CGM) system as part of a virtual diabetes clinic program improved their HbA1c and near-uniformly said they were comfortable self-inserting a sensor with guidance from a remote coach, according to study data presented by Onduo at an academic conference last weekend.
Further, while more than half of the study’s nearly 600...
Dexcom continuous glucose monitor users and their caregivers found themselves in the dark this weekend when a key monitoring feature ceased to function with little to no warning.
The feature, called Dexcom Follow, transmits an alert when a CGM user’s blood sugar reaches a dangerous level and is often used by parents monitoring their children’s condition. When unexpected issues brought down the...
New research set to be presented next week at the American College of Cardiology’s 68th Annual Scientific Session describes how the camera on a smartphone could be used to screen for Type 2 diabetes.
Diabetes is associated with changes to how blood flows through a person’s blood vessels, an effect that researchers from UCSF suggest could be used to detect early changes. By applying a deep...
At SXSW in Austin this weekend, consumer genomics company 23andMe unveiled its latest test, a predisposition report on Type 2 diabetes.
The test, which has not undergone FDA clearance and does not purport to diagnose a condition, is designed to help people understand when they’re at a higher-than-normal risk for Type 2 diabetes so they can alter their lifestyle. To assist with the latter piece,...
Earlier this month, Hygieia’s d-Nav Insulin Guidance Service — an app that titrates insulin doses for individual Type 2 diabetes patients, regardless of their regimen type — received 510(k) clearance from the FDA.
The cloud-based service leverages proprietary algorithms, users’ individual blood glucose data and a small team of in-house health professionals to generate and deliver insulin dosage...
